Connect to other sites within the UBM Medica Network
Final Results of 9-Valent HPV Vaccine Show Extended Cancer Protection
Final results of the trial that led to FDA approval show that a new 9-valent HPV vaccine can reduce cases of HPV and cervical cancer.
Prior Knowledge of MGUS Linked to Improved Multiple Myeloma Survival
Multiple myeloma patients had better overall survival if they had prior knowledge of having monoclonal gammopathy of undetermined significance.
FDA Approves Nivolumab (Opdivo) for NSCLC
The FDA has approved nivolumab (Opdivo) for the treatment of metastatic squamous non-small-cell lung cancer (NSCLC) in patients who have progressed on a platinum-based chemotherapy.
Time, the Irrational Ruler
While chatting with a patient of mine this week, I suddenly realized I had forgotten how long it had been since she was diagnosed. Time moves strangely in the world of cancer, too slow to comfort us, too fast in spiriting us away.
Personalized T-Cell Therapy for Brain Cancer
Researchers have shown that reprogramming T cells to target glioblastoma in mice resulted in control of these tumors.
Factors Used for Prognosis in Advanced Cervical Cancer
A new study yielded nomograms for the assessment of locally advanced cervical cancer, with prognostic factors including histology, performance status, and others.
Protecting Ovary Function During Breast Cancer Chemotherapy
The risk of early, sudden-onset menopause in women treated for early-stage breast cancer can be reduced with goserelin, a gonadotropin-releasing hormone agonist.
Fewer Lung Cancer Patients Eligible for Screening
A retrospective analysis suggested that a declining proportion of patients with lung cancer would meet the criteria for undergoing low-dose CT screening.
Patient Factors Linked With Ibrutinib Discontinuation
Researchers have identified patient factors linked with the discontinuation of ibrutinib therapy for reasons other than disease progression.
Ipilimumab Doubled 5-Year Survival in Advanced Melanoma
Advanced melanoma patients who received front-line ipilimumab/dacarbazine had double the 5-year survival rate compared with those on dacarbazine alone.
By clicking Accept, you agree to become a member of the UBM Medica Community.